Efficacy of a Tubeless Patch Pump in Patients With Type 2 Diabetes Previously Treated With Multiple Daily Injections.
作者信息
Layne Jennifer E, Parkin Christopher G, Zisser Howard
机构信息
1 Insulet Corporation, Billerica, MA, USA.
2 CGParkin Communications, Inc, Boulder City, NV, USA.
出版信息
J Diabetes Sci Technol. 2017 Jan;11(1):178-179. doi: 10.1177/1932296816653143. Epub 2016 Jul 9.
Abstract
摘要
相似文献
1
Efficacy of a Tubeless Patch Pump in Patients With Type 2 Diabetes Previously Treated With Multiple Daily Injections.
J Diabetes Sci Technol. 2017 Jan;11(1):178-179. doi: 10.1177/1932296816653143. Epub 2016 Jul 9.
2
Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus.
J Int Med Res. 2014 Aug;42(4):1002-10. doi: 10.1177/0300060514533523. Epub 2014 Jun 25.
3
Clinical Experience with U-500 Regular Insulin by Multiple Daily Injections and Continuous Subcutaneous Insulin Infusion.
Diabetes Technol Ther. 2017 Apr;19(4):220-225. doi: 10.1089/dia.2016.0411. Epub 2017 Mar 1.
4
[Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus].
Arch Pediatr. 2012 Jun;19(6):593-8. doi: 10.1016/j.arcped.2012.03.051. Epub 2012 May 14.
5
Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose.
Diabetes Metab. 2017 Sep;43(4):359-363. doi: 10.1016/j.diabet.2016.12.009. Epub 2017 Feb 21.
6
Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
J Med Econ. 2016;19(3):236-42. doi: 10.3111/13696998.2015.1113979. Epub 2015 Nov 19.
7
Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial.
Diabetes Obes Metab. 2017 Oct;19(10):1490-1494. doi: 10.1111/dom.12960. Epub 2017 Jul 25.
8
Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
Am J Manag Care. 2010;16(12):892-6.
9
Insulin pump therapy in adults.
Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S109-13. doi: 10.1016/S0168-8227(11)70025-0.
10
Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Diabetes Technol Ther. 2017 Jun;19(6):349-354. doi: 10.1089/dia.2016.0418. Epub 2017 Mar 15.
引用本文的文献
1
7. Diabetes Technology: Standards of Care in Diabetes-2025.
Diabetes Care. 2025 Jan 1;48(Supplement_1):S146-S166. doi: 10.2337/dc25-S007.
2
Impact of a tubeless, disposable insulin pump on emergency department visits and inpatient admissions among a Medicare population.
J Manag Care Spec Pharm. 2024 Oct;30(10):1128-1135. doi: 10.18553/jmcp.2024.23292. Epub 2024 Jun 17.
3
Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review.
Diabetes Ther. 2024 Jul;15(7):1525-1534. doi: 10.1007/s13300-024-01598-3. Epub 2024 May 21.
4
7. Diabetes Technology: Standards of Care in Diabetes-2024.
Diabetes Care. 2024 Jan 1;47(Suppl 1):S126-S144. doi: 10.2337/dc24-S007.
5
7. Diabetes Technology: Standards of Care in Diabetes-2023.
Diabetes Care. 2023 Jan 1;46(Suppl 1):S111-S127. doi: 10.2337/dc23-S007.
6
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations.
Diabetes Technol Ther. 2022 Nov;24(11):814-823. doi: 10.1089/dia.2022.0206. Epub 2022 Jul 26.
7
Phenolic Preservative Removal from Commercial Insulin Formulations Reduces Tissue Inflammation while Maintaining Euglycemia.
ACS Pharmacol Transl Sci. 2021 Apr 26;4(3):1161-1174. doi: 10.1021/acsptsci.1c00047. eCollection 2021 Jun 11.
8
Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.
Diabetes Technol Ther. 2021 Oct;23(10):715-725. doi: 10.1089/dia.2021.0196. Epub 2021 Jun 17.
9
Key Features of Insulin Delivery Devices for Type 2 Diabetes: Type 2.0 Booth Survey.
Clin Diabetes. 2020 Jan;38(1):56-61. doi: 10.2337/cd19-0014.
10
Treatment Intensification With Insulin Pumps and Other Technologies in Patients With Type 2 Diabetes: Results of a Physician Survey in the United States.
Clin Diabetes. 2020 Jan;38(1):47-55. doi: 10.2337/cd19-0008.
本文引用的文献
1
Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion.
J Diabetes Sci Technol. 2016 Aug 22;10(5):1130-5. doi: 10.1177/1932296816638674. Print 2016 Sep.
2
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
Lancet. 2014 Oct 4;384(9950):1265-72. doi: 10.1016/S0140-6736(14)61037-0. Epub 2014 Jul 2.
3
Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes.
Diabetes Technol Ther. 2012 May;14(5):411-7. doi: 10.1089/dia.2011.0228. Epub 2012 Jan 27.
4
Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: A retrospective claims analysis.
Prim Care Diabetes. 2010 Dec;4(4):209-14. doi: 10.1016/j.pcd.2010.07.004. Epub 2010 Sep 15.
5
Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes.
Diabetes Technol Ther. 2009 Aug;11(8):517-21. doi: 10.1089/dia.2008.0128.
6
Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.
Horm Metab Res. 2007 Mar;39(3):224-9. doi: 10.1055/s-2007-970423.
Zotero 插件